Comprehensive Development Support Oakwood Labs provides end-to-end solutions for long acting injectable development, covering feasibility, scale-up, and GMP manufacturing, offering a one-stop-shop experience that can attract clients seeking streamlined project management.

Innovative Technology With its proprietary sustained release microsphere technology capable of tailored release profiles, Oakwood Labs can appeal to pharmaceutical companies looking for advanced delivery systems to differentiate their long acting injectable products.

Industry Collaborations Recent partnerships, such as with Edge Therapeutics for EG-1962, demonstrate Oakwood’s capacity for manufacturing specialty products and its strategic role as a reliable manufacturing partner for innovative therapies.

Market Position & Revenue Generating between $50M and $100M, Oakwood Labs operates within a competitive segment with peers like DURECT and Adare Pharma, indicating potential opportunities for partnerships targeting niche injectables and sustained release formulations.

Expansion & Capabilities With a team of up to 200 employees and focus on aseptic GMP manufacturing, Oakwood Labs is positioned to scale with growing demand in biologics and injectable markets, presenting growth prospects for clients seeking reliable manufacturing infrastructure.